



東瑞製葯（控股）有限公司
Dawnrays Pharmaceutical (Holdings) Limited

(Incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立的有限公司)

Suites 3212-13, Shell Tower, Times Square, 1 Matheson Street, Hong Kong

Tel: 852-2111 9708 Fax: 852-2111 9870

FOR IMMEDIATE RELEASE

PRESS RELEASE

Attn: Business Editor

Dawnrays Pharmaceutical (Holdings) Limited

Levamlodipine Besylate Tablets, A Cardiovascular Therapeutic Drug and Cefprozil Tablets, An Oral Cephalosporin Antibiotic, have been granted production approvals from the State Food and Drug Administration

(Hong Kong, 14 March 2011) **Dawnrays Pharmaceutical (Holdings) Limited** (“Dawnrays Pharma” or the “Group”, The Stock Exchange of Hong Kong Stock Code: 2348) announced that Levamlodipine Besylate Tablets (苯磺酸左旋氨氯地平片)(Trade name: 安美平[®] (Anmeiping)), a cardiovascular therapeutic drug and Cefprozil Tablets (頭孢丙烯片) (Trade name: 司力可[®] (Silike)), an oral cephalosporin antibiotic, two new generic drugs of Suzhou Dawnrays Pharmaceutical Co., Ltd., a subsidiary of the Group, have been granted production approvals from the State Food and Drug Administration (SFDA), the approval numbers are Guo Yao Zhun Zi (國藥准字) H20103814 and Guo Yao Zhun Zi (國藥准字) H20103792 respectively, and anticipates their production and sales will start in the near term.

In the past 8 years, Dawnrays Pharma has been eager to make enthusiastic progress in the cardiovascular field. The key product 安內真[®] (Anneizhen) and related series of products have a rapid growth in sales in recent years. At the same time, with the implementation of the “Chinese Hypertension Intervention Efficacy Study” (“CHIEF” study) under the National Science and Technology Pillar Program during the “Eleventh Five-year Plan” period (國家「十一·五」科技支撐計劃「高血壓綜合防治研究」) is bringing into practice, the Group has gradually formed a stronger brand dominance. Thus, turned into one of the significant sources of profit for the Group. The soon to be marketed Levamlodipine Besylate Tablets (苯磺酸左旋氨氯地平片) has been included in the National Essential Drug List (國家基本藥物目錄) in various provinces and cities in China. The market size is over

RMB one billion yuan as there is a wide range of patients population. This product and the original series of 安內真[®] (Anneizhen) can complement each other and so it would complete and enrich the cardiovascular product line of the Group. And it is expected to further expand the Group's sales volume of cardiovascular therapeutic drugs.

Cefprozil Tablets (頭孢丙烯片) is a new type of the second generation cephalosporin for oral use. It has been included in the National Medical Insurance Catalogue (國家醫保目錄). Affected by the continuity of reinforcement to the Antibiotics Use Standard in China, the new type of second generation cephalosporin for oral use has larger market demand. To inherit Dawnrays Pharma's powerful production capacity in cephalosporin antibiotics territory, the prudent marketing strategy and the extensive coverage distribution network, the Group anticipates this product will accomplish a speedy market penetration after launch, effectively improve the Group's market share in the field of cephalosporin antibiotic drugs for oral use.

About “Chinese Hypertension Intervention Efficacy Study” (“CHIEF” Study) 「高血壓綜合防治研究」

Dawnrays Pharma participated in the “Chinese Hypertension Intervention Efficacy Study” in 2007 by supplying drugs for the research for a duration of five years and was appointed as the exclusive research and cooperation partner and designated supplier for drugs used in research. “CHIEF Study” is a key technology project jointly supported by the Ministry of Health and Ministry of Science and Technology of the P.R. China under the State's Eleventh Five-Year Plan. It is then the largest integrated clinical research project of its kind in China, involving more than 150 clinical centres and 13,000 hypertensive patients nationwide.

Dawnrays Pharma's participation in the project is on the basis of improving the general health and well beings of human lives, and supported by a comprehensive range of antihypertensive products of the Group, including ARB drug Telmisartan Tablets (替米沙坦片)(Trade name: 安內強[®] (Anneiqiang)), Potassium-sparing Diuretic Compound Amiloride Hydrochloride Tablets (複方鹽酸阿米洛利片)(Trade name: 安利亞[®] (Anliya)) and Amlodipine Besylate Tablets (苯磺酸氨氯地平片)(Trade name: 安內真[®] (Anneizhen)), the most prescribed drugs among calcium-channel blockers in China, and etc.

About Dawnrays Pharmaceutical (Holdings) Limited

Dawnrays Pharmaceutical (Holdings) Limited (Stock Code: 2348) is a leading vertically integrated pharmaceutical group in China with core competencies in the manufacturing of cephalosporins and system specific medicines. Founded in 1995, the Group was listed on the Main Board of the Stock Exchange of Hong Kong in July 2003.

Dawnrays Pharma is among one of the earliest pharmaceutical companies in China granted the GMP certification. The Group is principally engaged in the development, manufacturing and sales of cephalosporins and various system specific medicines. Dawnrays Pharma is one of the few comprehensive vertically integrated 3rd generation cephalosporin manufacturers in China, adopting distinctive production process from pharmaceutical intermediates to bulk medicines and pharmaceutical preparations. Its system specific medicines cover a wide range of therapeutic areas for cardiovascular system, anti-viral, anti-allergic, digestive system, urinary system and endocrine system, etc. The dosage forms of the Group's pharmaceutical preparations include powder for injections, tablets, capsules and granules, etc.

— End —

This press release is issued by Dawnrays Pharmaceutical (Holdings) Limited.
For further enquiries, please contact:

Vanessa Yeung / Michelle Li
Corporate Communications
Tel : 852-2111 9708
Fax : 852-2111 9870
Email : ir@dawnrays.com.hk